Zheng Xing Xing Ye Ri Bao·2026-01-16 08:56Market Overview - The Chinese medicine sector experienced a decline of 0.59% on January 16, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 4101.91, down 0.26%, while the Shenzhen Component Index closed at 14281.08, down 0.18% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Tianmu Pharmaceutical (600671) with a closing price of 18.41, up 4.07% [1] - Zhongsheng Pharmaceutical (002317) at 22.10, up 3.32% [1] - Weikang Pharmaceutical (300878) at 32.84, up 2.34% [1] - Conversely, *ST Changyao (300391) saw a significant drop of 20.59%, closing at 0.54 [2] Trading Volume and Value - The trading volume and value for selected stocks were as follows: - Zhongsheng Pharmaceutical had a trading volume of 862,100 shares and a transaction value of 1.854 billion [1] - Weikang Pharmaceutical recorded a trading volume of 161,200 shares with a transaction value of 207 million [1] - The overall net outflow of funds in the Chinese medicine sector was 299 million, while retail investors saw a net inflow of 62.16 million [2] Fund Flow Analysis - Major fund flows indicated: - Zhongsheng Pharmaceutical had a net inflow of 1.57 billion from major funds, but a net outflow of 22.56 million from speculative funds [3] - Yunnan Baiyao (000538) saw a net inflow of 61.66 million from major funds, with a net outflow of 24.37 million from speculative funds [3] - The overall sentiment reflected a mixed response from different investor categories, with major funds showing a preference for certain stocks while speculative funds exhibited outflows [3]